Curb the pain of the #1 cost driver in healthcare
Rezilient Musculoskeletal Health is evidence-based physical therapy that gets people moving with less pain.
Combining MSK therapy with primary care is proven to have better outcomes than MSK-only solutions.
Rezilient Musculoskeletal Health combines our in-person CloudClinics with our remote specialists for the expert care people need to move without pain again, without the long wait that comes with traditional specialists.
Our innovative digital MSK health platform reduces absenteeism and unnecessary and often costly medical interventions, such as imaging, opioids, and surgery.
WHY REZILIENT APC?
Our integrated MSK Health program leads to better results and lower costs through unified, whole person care.
Employer pays one set monthly fee
Employees get $0 out-of-pocket access to healthcare
Employees navigated to specialists within the health plan, when required
Employer sees lower overall healthcare costs and a healthier population
WHY WORK WITH US
Curb the #1 cost driver
MSK now accounts for the most amount of healthcare spending of any condition.
Our integrated MSK Health platform reduces absenteeism and unnecessary and often costly medical interventions, such as imaging, opioids, and surgery.
Free people from pain
1 out of 2 employees experience musculoskeletal pain each year, most commonly lower back, hip, knee, neck, and shoulder injuries.
Integrating exercise therapy with primary care, education, and advice is proven to improve adherence and get people moving again, free from pain.
Remove barriers to care
Less than 12% of MSK patients adhere to traditional physical therapy programs because of cost and time.
Rezilient MSK Health removes the biggest barriers to adherence with $0 co-pays and same-day appointments for better outcomes.
We’re here to help.
Talk to our expert team to find out how Rezilient could change your healthcare game.
Latest Insights
Introducing Rezilient Multispecialty Care
Our new Multispecialty Care vertical allows us to introduce focused specialty programs to address the most critical healthcare needs of our patient populations.
Danish Nagda included in the St. Louis Business 500
Danish Nagda named as one of the region's top business leaders
Is the GLP-1 compounding boom over?
The FDA has officially declared an end to the supply squeeze on Novo Nordisk's GLP-1 semaglutide, which is also branded as Ozempic and Wegovy.
How our hybrid model outperforms traditional primary care
When we first evaluated our hybrid care model, our first goal was to maintain high quality care without the doctor in the room.